SEC Form 4 · accession 0001104659-16-145695
Aegerion Pharmaceuticals, Inc. · AEGR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Benjamin Harshbarger
Officer — General Counsel
Period of report
Apr 1, 2016
Accepted (ET)
Sep 20, 2016 · 4:03 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001338042
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Apr 1, 2016 | M | 867 | — | A | 867 | D | |
| Common Stock | Apr 1, 2016 | F | 273 | $3.55 | D | 594 | D | |
| Common StockF1 | Sep 17, 2016 | M | 1,642 | — | A | 2,236 | D | |
| Common Stock | Sep 17, 2016 | F | 532 | $1.78 | D | 1,704 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF1,F2 | — | Apr 1, 2016 | M | 867 | D | — | — | Common Stock | 867 | 1,733 | D |
| Restricted Stock UnitsF1,F3 | — | Sep 17, 2016 | M | 1,642 | D | — | — | Common Stock | 1,642 | 3,282 | D |
Explanation of responses
- F1Each restricted stock unit represents a contingent right to receive one share of common stock.
- F233.34% of the grant vested on April 1, 2016. Subject, with limited exceptions, to the Reporting Person's continued employment with the Issuer, an additional 33.33% of the units will vest on each of April 1, 2017 and April 1, 2018.
- F333.34% of the grant vested on September 17, 2016. Subject, with limited exceptions, to the Reporting Person's continued employment with the Issuer, an additional 33.33% of the units will vest on each of September 17, 2017 and September 17, 2018.